By: Danny Sullivan
Antag lands €80m to advance GIPR antagonist approach discovered by researcher behind GLP-1 obesity drugs.
Danny Sullivan is a Contributing Editor at Defector Media LLC and Longevity.Technology. With over 15 years of experience in technology communications across Europe and North America, he covers a wide range of topics including medicine and healthcare, diagnostics, and the intersection of science and technology, with a specific interest in the transition from idea to market. Danny's work has been featured in notable publications such as Defector Media LLC and Longevity.Technology.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Danny Sullivan's coverage primarily focuses on healthcare, pharmaceuticals, and scientific advancements related to longevity research, biotechnology, aging, and medical breakthroughs. His articles often include press releases and private sector announcements.
To effectively reach out to Danny Sullivan, consider providing information about new developments in the aforementioned fields or offering interviews with key figures from relevant companies or organizations involved in these areas. Additionally, if there are specific data-driven insights or analyses related to longevity research or healthcare funding that can contribute to his coverage themes, those would likely be of interest as well.
This information evolves through artificial intelligence and human feedback. Improve this profile .